Latest Supply Agreements News

ABx Group Limited has reported significant progress across its rare earths, fluorine chemical, and bauxite mining projects, underpinned by a $6 million capital raise and promising metallurgical results.

KALiNA Power has strengthened its financial position by selling a 180 MW load allocation for C$18 million, while advancing its Alberta gas-fired power projects amid evolving regulatory frameworks.

Elixinol Wellness Ltd reported a 9.5% revenue increase in Q4 FY25 alongside a 30% cut in operating costs, achieving its first underlying operating cash flow positive quarter. The company’s strategic acquisitions and e-commerce growth underpin a clear path to profitability.

Horizon Oil reported an 18% rise in production and sales volumes in Q2 FY26, driven by its first full quarter of Thailand asset output. The company also maintained strong cashflow, paid a final FY25 dividend, and secured a long-term gas supply agreement in Australia’s Northern Territory.

Metallium Limited has kicked off commissioning at its Texas Technology Campus, sealed a multi-year feedstock deal with Glencore, and bolstered its balance sheet with a A$75 million capital raise, setting the stage for commercialisation in 2026.

Atomo Diagnostics reported a robust 121% quarter-on-quarter revenue increase to $1.5 million, driven by new orders for its FebriDx Pascal and HIV Self-Test products. The company also secured a global licensing deal for a novel liver function test and expanded manufacturing capacity to support growing demand.

Algorae Pharmaceuticals has advanced its AI drug discovery capabilities with the launch of AlgoraeOS v2 and secured key commercial partnerships, including a $3 million debt facility to support expansion in Australia and New Zealand.

Woodside Energy reported record production for 2025, exceeding guidance while progressing key LNG and ammonia projects. The company also navigates a CEO transition and strategic asset sales.

Bioxyne Limited has reported a record $17.2 million in quarterly revenue, driven by strong growth in its cannabis and psychedelics segments, alongside strategic international expansions including a Frankfurt dual listing and new manufacturing agreements.

Bioxyne Limited has posted a record $17.2 million in quarterly revenue for Q2 FY26, driven by strong growth in its cannabis and psychedelics segments alongside strategic international expansions.

Tetratherix Limited (ASX, TTX) reports significant progress in clinical trials, strategic partnerships, and manufacturing capacity, positioning itself for near-term commercialisation and sustained innovation.

AnteoTech has raised A$3.5 million through a discounted share placement to accelerate commercialisation of its advanced battery and life sciences technologies globally. The capital injection supports strategic partnerships and sales expansion in key markets including the US and India.